Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Regeneron ...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $850.00. According to TipR...

Regeneron (REGN) Receives a Buy from BMO Capital

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Regeneron yesterday and set a price target of $745.00. According to TipRanks, Bansal i...

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Regeneron, with a price target of $708.00. According to Tip...

RBC Capital Sticks to Its Hold Rating for Regeneron (REGN)

The Invesco QQQ ETF ($QQQ) rose 0.81% on Friday, with major indices ending the last trading session of November on a positive note. However, Novemb...

QQQ ETF Daily Update, 12/1/2025

Analysts are intrested in these 5 stocks: ( ($EXAS) ), ( ($REGN) ), ( ($MRVL) ), ( ($FROG) ) and ( ($JAZZ) ). Here is a breakdown of their recent


Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts

The Invesco QQQ ETF ($QQQ) rose 0.88% on Wednesday as major averages closed higher for the fourth straight day, ahead of the Thanksgiving holiday. ...

QQQ ETF News, 11/27/2025

Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

Current Yield	3.52%	Payout Ratio	18.25%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	11/20/2025	Pay Date	12/5/2025
Frequency	Unspecified	Quarterly Est	$0.00

Date	Nov 2025	Stock Price	$737.00	TTM Div	$3.52	Yield	0.48%
Date	Aug 2025	Stock Price	$737.00	TTM Div	$2.64	Yield	0.36%
Date	May 2025	Stock Price	$737.00	TTM Div	$1.76	Yield	0.24%
Date	Feb 2025	Stock Price	$737.00	TTM Div	$0.88	Yield	0.12%

Date	11/20/2025	Amount	$0.88	Currency	USD	Frequency	Q
Date	8/18/2025	Amount	$0.88	Currency	USD	Frequency	Q
Date	5/20/2025	Amount	$0.88	Currency	USD	Frequency	Q
Date	2/20/2025	Amount	$0.88	Currency	USD	Frequency	U

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$741.29	-0.74%	804.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$741.29	-0.7%	804.84K
3
4
5
6

REGN

REGN

Dividend Overview

Dividend Yield History

Stock Price

TTM Dividend Payout

TTM Dividend Yield

Historical Yield Data

Recent Dividend History

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel